Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million on October 30, 2023. Shanghai Fujian Equity Investment Fund Management reported Total assets worth CNY 84.05 million and Total common equity of CNY 55.51 million as on September 30, 2023. Such consideration will be settled in cash by self-raised funds of the Company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.69 CNY | -1.17% | -1.99% | -5.35% |
May. 15 | Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment | MT |
May. 15 | China Approves Clinical Trials For Breast Cancer Drugs | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.35% | 7.97B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Shanghai Fosun Pharmaceutical Co., Ltd. acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.